Cocrystal Pharma Inc (STU:8CC)
€ 1.96 -0.01 (-0.51%) Market Cap: 20.23 Mil Enterprise Value: 9.68 Mil PE Ratio: 0 PB Ratio: 1.68 GF Score: 36/100

Cocrystal Pharma Inc at Noble Capital Markets Investor Conference (Virtual) Transcript

Apr 21, 2022 / 01:30PM GMT
Release Date Price: €5.78 (+4.15%)
James Martin
Cocrystal Pharma, Inc. - Co-CEO & CFO

Hello, everyone. I'd like to start by thanking Noble for hosting this conference and for all of you for your interest in Cocrystal Pharma. These are forward-looking statements. I encourage you to read them along with our SEC filings.

So about Cocrystal, we're an antiviral company. We advance high-value antiviral therapeutic drugs. This differentiates us from a vaccine company, and that we do not create vaccines; vaccines are more preventative. We create therapeutics to treat the disease once you have it. This is all driven by our drug discovery platform that was derived from our founders, one of them beyond Nobel Laureate. He took his Nobel experience and put it into a platform to discover drugs.

The investment highlights here at Cocrystal are that we target large global markets where treatment of both acute and pandemic viral diseases. Again, we do have a very strong drug discovery platform that we've developed from our founders and has been used by Merck to develop compounds. We have a number of programs. I think the most

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot